FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283161781> ?p ?o ?g. }

• W4283161781 endingPage "74" @default.
• W4283161781 startingPage "67" @default.
• W4283161781 abstract "Objective: to evaluate the efficacy and safety of the parenteral form of pharmaceutical chondroitin sulfate (CS) in neuroimmune joint damage in patients with early knee osteoarthritis (OA) in long COVID. Patients and methods . An open prospective controlled randomized study was conducted, its duration was 50 days of active controlled therapy. The study included 82 patients (age 57–63 years, men – 29, women – 53) with clinical symptoms of early knee OA and confirmed long COVID type 2 (persistence of symptoms 4–12 weeks after infection with SARS-CoV2). The diagnosis of OA was established in accordance with the updated classification criteria for early knee OA (2018).Patients were randomized into two groups: group 1 – the main group (n=42) and group 2 – control group (n=40). Patients in both groups received celecoxib at a dose of 200 mg with the possibility of reducing the dose to 100 mg or completely discontinuing the drug if necessary. Patients of the 1st group additionally received a parenteral form of CS (Chondroguard® solution for intramuscular and intraarticular administration, 100 mg/ml). At baseline (Day 1) and on the 50th day of the study, pain intensity was assessed in all patients using a visual analogue scale (VAS), the degree of functional impairment (FI) of the joints according to the Lequesne index, ultrasound of the knee joint was performed, CRP, D-dimer, fibrinogen, interleukin (IL) 1β, IL6 levels were studied. The presence of SARS-CoV2 was determined by polymerase chain reaction in scrapings from the mucous membrane of the nasal cavity and oropharynx, and a qualitative proteomic analysis was performed (1-2DE, MALDI-TOF/TOF-MS, PathCards database). The safety of therapy was assessed using the WHO and Naranjo scales. Results and discussion . It was established that CS therapy was well tolerated and was accompanied by a significant decrease in pain intensity according to VAS (U-test=5.71; p<0.0001), in FI according to the Lequesne scale (U-test=6.32; p<0.0001), in manifestations of synovitis and tendinitis in the group treated with CS and celecoxib, compared with the control group. During the treatment by CS a statistically significant (p<0.0001) decrease in the level of pro-inflammatory markers in the blood serum (CRP, IL6, IL1β), D-dimer and fibrinogen was noted. Proteomic analysis showed a decrease in the blood serum of patients of the 1st group of eotaxin 1, IL8, IL15, interferon γ inducible protein 10 levels, and an increase in the expression of nerve fiber growth factor β, an antagonist of the IL1 receptor. Conclusion . The use of pharmaceutical parenteral CS in combination with oral celecoxib in patients with early OA of the knee joint, the clinical signs of which manifested after infection with SARS-CoV2 and persisted in long COVID conditions, contributed to a decrease in the severity of pain and stiffness in the knee joint, as well as improved functional capabilities." @default.
• W4283161781 created "2022-06-21" @default.
• W4283161781 creator A5004963520 @default.
• W4283161781 creator A5019041776 @default.
• W4283161781 creator A5087988635 @default.
• W4283161781 date "2022-06-19" @default.
• W4283161781 modified "2023-09-23" @default.
• W4283161781 title "Current possibilities of pharmacological correction of neuroimmune joint damage in patients with knee osteoarthritis in long COVID conditions" @default.
• W4283161781 cites W1568081300 @default.
• W4283161781 cites W165302982 @default.
• W4283161781 cites W2107894170 @default.
• W4283161781 cites W2265780753 @default.
• W4283161781 cites W2507683743 @default.
• W4283161781 cites W2531097686 @default.
• W4283161781 cites W3016502272 @default.
• W4283161781 cites W3212405793 @default.
• W4283161781 doi "https://doi.org/10.14412/1996-7012-2022-3-67-74" @default.
• W4283161781 hasPublicationYear "2022" @default.
• W4283161781 type Work @default.
• W4283161781 citedByCount "1" @default.
• W4283161781 countsByYear W42831617812022 @default.
• W4283161781 crossrefType "journal-article" @default.
• W4283161781 hasAuthorship W4283161781A5004963520 @default.
• W4283161781 hasAuthorship W4283161781A5019041776 @default.
• W4283161781 hasAuthorship W4283161781A5087988635 @default.
• W4283161781 hasBestOaLocation W42831617811 @default.
• W4283161781 hasConcept C126322002 @default.
• W4283161781 hasConcept C141071460 @default.
• W4283161781 hasConcept C14184104 @default.
• W4283161781 hasConcept C142724271 @default.
• W4283161781 hasConcept C168563851 @default.
• W4283161781 hasConcept C204787440 @default.
• W4283161781 hasConcept C2776164576 @default.
• W4283161781 hasConcept C2776467144 @default.
• W4283161781 hasConcept C2779519742 @default.
• W4283161781 hasConcept C2908736133 @default.
• W4283161781 hasConcept C42219234 @default.
• W4283161781 hasConcept C71924100 @default.
• W4283161781 hasConcept C90924648 @default.
• W4283161781 hasConceptScore W4283161781C126322002 @default.
• W4283161781 hasConceptScore W4283161781C141071460 @default.
• W4283161781 hasConceptScore W4283161781C14184104 @default.
• W4283161781 hasConceptScore W4283161781C142724271 @default.
• W4283161781 hasConceptScore W4283161781C168563851 @default.
• W4283161781 hasConceptScore W4283161781C204787440 @default.
• W4283161781 hasConceptScore W4283161781C2776164576 @default.
• W4283161781 hasConceptScore W4283161781C2776467144 @default.
• W4283161781 hasConceptScore W4283161781C2779519742 @default.
• W4283161781 hasConceptScore W4283161781C2908736133 @default.
• W4283161781 hasConceptScore W4283161781C42219234 @default.
• W4283161781 hasConceptScore W4283161781C71924100 @default.
• W4283161781 hasConceptScore W4283161781C90924648 @default.
• W4283161781 hasIssue "3" @default.
• W4283161781 hasLocation W42831617811 @default.
• W4283161781 hasOpenAccess W4283161781 @default.
• W4283161781 hasPrimaryLocation W42831617811 @default.
• W4283161781 hasRelatedWork W2006253988 @default.
• W4283161781 hasRelatedWork W2358110111 @default.
• W4283161781 hasRelatedWork W2362787732 @default.
• W4283161781 hasRelatedWork W2364759832 @default.
• W4283161781 hasRelatedWork W2369726855 @default.
• W4283161781 hasRelatedWork W2982577320 @default.
• W4283161781 hasRelatedWork W3029457321 @default.
• W4283161781 hasRelatedWork W3032572458 @default.
• W4283161781 hasRelatedWork W3169016788 @default.
• W4283161781 hasRelatedWork W3186166137 @default.
• W4283161781 hasVolume "16" @default.
• W4283161781 isParatext "false" @default.
• W4283161781 isRetracted "false" @default.
• W4283161781 workType "article" @default.